Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.
Prostate cancer (PC) is one of the leading causes of cancer-related deaths among men globally, and it frequently coexists with cardiovascular disease (CVD). With increasing cancer survival rates and an aging population, the incidence of CVD among PC patients is also on the rise. The treatments for PC include androgen deprivation therapy, androgen receptor pathway inhibitors, and docetaxel-based chemotherapy, and the cardiovascular complications include hypertension, metabolic syndrome, heart failure and arrhythmias. As it is important to provide personalized treatment planning and close monitoring, cardio-oncology collaboration plays a crucial role in optimizing treatment outcomes, emphasizing cardiovascular risk assessments and tailored treatment plans that balance cancer control and cardiovascular health. In this consensus statement, we review several important issues including the association between CVD and PC, screening for cardiovascular diseases and risk factors, timing and criteria for cardiology referral, cardiovascular risk assessments and management, and multidisciplinary collaboration and patient education. However, challenges remain in screening and preventive measures, and future research should focus on developing robust cardiovascular risk assessment tools, preventive measures, and interdisciplinary approaches to improve patient outcomes and reduce cardiovascular morbidity in patients being treated for PC.
Authors
- Ping‐Yen Liu (ORCID: https://orcid.org/0000-0002-3643-5204)
- Wen‐Jone Chen (ORCID: https://orcid.org/0000-0002-2098-5922)
- Kai‐Hung Cheng (ORCID: https://orcid.org/0000-0003-1066-9499)
- See‐Tong Pang (ORCID: https://orcid.org/0000-0002-2064-0828)
- Kuan‐Hua Huang (ORCID: https://orcid.org/0000-0001-9102-1920)
- I‐Hung Shao (ORCID: https://orcid.org/0000-0002-4832-0113)
- Wei‐Ting Chang (ORCID: https://orcid.org/0000-0001-9525-2144)
- Dong‐Yi Chen (ORCID: https://orcid.org/0000-0002-9544-5496)
- Wen-Hwa Wang
- Sheng-Chun Hung (ORCID: https://orcid.org/0000-0002-7358-6335)
- Pei-Jhang Chiang (ORCID: https://orcid.org/0000-0003-2238-5012)
- Chao‐Yuan Huang (ORCID: https://orcid.org/0000-0002-9322-6062)
- Yen‐Chou Chen (ORCID: https://orcid.org/0000-0002-5960-6483)
- Chung-Lieh Hung
- Hung‐Ju Lin (ORCID: https://orcid.org/0000-0003-2449-9072)
- Tzung‐Dau Wang (ORCID: https://orcid.org/0000-0002-7180-3607)
- Shian‐Shiang Wang (ORCID: https://orcid.org/0000-0003-3032-0198)
- Yen‐Wen Wu (ORCID: https://orcid.org/0000-0003-1520-1166)
- Tzu-Ping Lin
- Yi‐Heng Li (ORCID: https://orcid.org/0000-0003-0390-2360)
- Jen‐Tai Lin (ORCID: https://orcid.org/0000-0001-7702-5562)
- Jin‐Liern Hong (ORCID: https://orcid.org/0000-0001-9483-6316)
- Jo-Nan Liao
- Shu‐Pin Huang
- Tai‐Lung Cha (ORCID: https://orcid.org/0000-0003-3569-771X)
- Hsi‐Chin Wu
Institutions
- Tri-Service General Hospital (TW)
- National Yang Ming Chiao Tung University (TW)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
- China Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Kaohsiung Veterans General Hospital (TW)
- National Cheng Kung University Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- PubMed
- Published
- 2025-05-01
- DOI
- https://doi.org/10.6515/acs.202505_41(3).20250224a
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39